Document is current
Any future updates will be listed below
-
Authors
Morlion, Annelien https://orcid.org/0000-0003-1791-2359
Decruyenaere, Philippe
Schoofs, Kathleen
Anckaert, Jasper https://orcid.org/0000-0001-8144-4639
Johns Ramirez, Nickolas
Nuytens, Justine https://orcid.org/0000-0002-4878-1200
Vanden Eynde, Eveline https://orcid.org/0000-0003-0454-4171
Verniers, Kimberly https://orcid.org/0000-0002-7693-5908
Everaert, Celine https://orcid.org/0000-0001-7772-4259
Brusselle, Guy
Callens, Steven
Haerynck, Filomeen
Hemelsoet, Dimitri https://orcid.org/0000-0001-5403-3092
Hoste, Eric
Lambert, Jo https://orcid.org/0000-0001-5303-9310
Lumen, Nicolaas
Offner, Fritz
Paemeleire, Koen
Smith, Vanessa
Van den Eynde, Lies https://orcid.org/0009-0008-3664-9174
Van Dorpe, Jo https://orcid.org/0000-0001-8175-2930
Vanhaecke, Amber
Van Vlierberghe, Hans
Mariman, An https://orcid.org/0009-0005-8131-9316
Thas, Olivier
Vandesompele, Jo https://orcid.org/0000-0001-6274-0184
Mestdagh, Pieter https://orcid.org/0000-0001-7821-9684
- License Information
-
More Information
Article History
Received: 29 January 2026
Accepted: 24 February 2026
First Online: 7 March 2026
Competing interests
: A.M., J.V., and P.M. are inventors on the international PCT application “Method to screen, diagnose or monitor treatment using increased numbers of deviating analytes” (WO2024200811; published 03/10/2024) covering the tail gene concept. They are also inventors on the European priority application “Blood plasma RNA profiles enable accurate diagnosis of prostate cancer” (EP26151329.5; filed 12/01/2026) covering specific prostate cancer biomarker tail genes from the prostate cancer cohort in this manuscript. Both applications are assigned to Ghent University.
